Meeting of the National Vaccine Advisory Committee, 3172-3173 [2018-01142]

Download as PDF 3172 Federal Register / Vol. 83, No. 15 / Tuesday, January 23, 2018 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Announcement of Meeting of the Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030 Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The U.S. Department of Health and Human Services (HHS) announces the next meeting of the Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030 (Committee) regarding the development of national health promotion and disease prevention objectives for 2030. This meeting will be held online via webinar and is open to the public. The Committee will discuss the nation’s health promotion and disease prevention objectives and will provide recommendations to improve health status and reduce health risks for the nation by the year 2030. The Committee will develop recommendations regarding: Leading Health Indicators; the setting of targets for a more focused set of measurable, nationally representative objectives; the roles of health and well-being, health equity, and law in Healthy People 2030; and the creation of a logic model for communicating the role of Healthy People 2030, disease prevention, and health promotion. Pursuant to the Committee’s charter, the Committee’s advice must assist the Secretary in reducing the number of objectives while ensuring that the selection criteria identifies the most critical public health issues that are high-impact priorities supported by current national data. DATES: The Committee will meet on February 28, 2018, from 2:00 p.m. to 5:00 p.m. Eastern Time (ET). ADDRESSES: The meeting will be held online via webinar. To register to attend the meeting, please visit the Healthy People website at https:// www.healthypeople.gov. SUMMARY: sradovich on DSK3GMQ082PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Emmeline Ochiai, Designated Federal Official, Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, VerDate Sep<11>2014 17:59 Jan 22, 2018 Jkt 244001 Room LL–100, Rockville, MD 20852, (240) 453–8280 (telephone), (240) 453– 8281 (fax). Additional information is available on the Healthy People website at https://www.healthypeople.gov. SUPPLEMENTARY INFORMATION: The names and biographies of the Committee members are available at https://www.healthypeople.gov/2020/ about/history-development/healthypeople-2030-advisory-committee. Purpose of Meeting: Through the Healthy People initiative, HHS leverages scientific insights and lessons from the past decade, along with new knowledge of current data, trends, and innovations, to develop the next iteration of national health promotion and disease prevention objectives. Healthy People provides science-based, 10-year national objectives for promoting health and preventing disease. Since 1979, Healthy People has set and monitored national health objectives that meet a broad range of health needs, encourage collaboration across sectors, guide individuals toward making informed health decisions, and measure the impact of our prevention and health promotion activities. Healthy People 2030 health objectives will reflect assessments of major risks to health and wellness, changing public health priorities, and emerging technologies related to our nation’s health preparedness and prevention. Public Participation at Meeting: Members of the public are invited to join the online Committee meeting. There will be no opportunity for oral public comments during this online Committee meeting. However, written comments are welcome throughout the entire development process of the national health promotion and disease prevention objectives for 2030 and may be emailed to HP2030@hhs.gov. To join the Committee meeting, individuals must pre-register at the Healthy People website at https:// www.healthypeople.gov. Participation in the meeting is limited. Registrations will be accepted until maximum webinar capacity is reached and must be completed by 9:00 a.m. ET on February 28, 2018. A waiting list will be maintained should registrations exceed capacity and those individuals will be contacted as additional space for the meeting becomes available. Registration questions may be directed to HealthyPeople@norc.org. Authority: 42 U.S.C. 300u and 42 U.S.C. 217a. The Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030 is governed by provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C., App.) which sets forth PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 standards for the formation and use of federal advisory committees. Dated: January 17, 2018. Don Wright, Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion). [FR Doc. 2018–01143 Filed 1–22–18; 8:45 am] BILLING CODE 4150–32–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee National Vaccine Program Office, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services is hereby giving notice that a meeting is scheduled to be held for the National Vaccine Advisory Committee (NVAC). The meeting will be open to the public; public comment sessions will be held during the meeting. DATES: The meeting will be held on February 7 and 8, 2018. The meeting times and agenda will be posted on the NVAC website at https://www.hhs.gov/ nvpo/nvac/meetings/ as soon as they become available. ADDRESSES: U.S. Department of Health and Human Services, Hubert H. Humphrey Building, Great Hall, 200 Independence Avenue SW, Washington, DC 20201. The meeting can also be accessed through a live webcast on both days of the meeting. For more information, visit https://www.hhs.gov/ nvpo/nvac/meetings/. Pre-registration is required for members of the public who wish to attend the meeting and who wish to participate in the public comment session. Individuals who wish to attend the meeting and/or participate in the public comment session should register at https://www.hhs.gov/nvpo/nvac/ meetings/. Participants may also register by emailing nvpo@hhs.gov or by calling (202) 690–5566 and providing their name, organization and email address. FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S. Department of Health and Human Services, Room 715H, Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. Phone: (202) 690–5566; email: nvac@ hhs.gov. SUMMARY: E:\FR\FM\23JAN1.SGM 23JAN1 Federal Register / Vol. 83, No. 15 / Tuesday, January 23, 2018 / Notices Pursuant to Section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of Health and Human Services was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. During the February 2018 NVAC meeting, sessions will consist of presentations on vaccine innovation, including the current status of adjuvants in vaccines, universal influenza, and an overview on the Secretary of the Department of Health and Human Services’ Report to Congress on Vaccine Innovation in response to the 21st Century Cures Act; a report out on the recently approved Presidential Advisory Council on Combatting Antibiotic-Resistant Bacteria Report, ‘‘Incentivizing the Development of Vaccines, Therapeutics, and Diagnostics to Combat Antibiotic Resistant Bacteria’’; disparities in adult immunizations; and an update on strategies to support improving coverage for human papillomavirus vaccine. Please note that agenda items will be related to the charge of the Committee and are subject to change as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: https:// www.hhs.gov/nvpo/nvac/. Public attendance at the meeting is limited to the available space. Individuals who plan to attend in person and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the National Vaccine Program Office at the address/phone number listed above at least one week prior to the meeting. For those unable to attend in person, a live webcast will be available. More information on registration and accessing the webcast can be found at https://www.hhs.gov/ nvpo/nvac/meetings/. Members of the public will have the opportunity to provide comments at the NVAC meeting during the public comment periods designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Individuals are also welcome to submit their written comments. Written comments should not exceed three sradovich on DSK3GMQ082PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 17:59 Jan 22, 2018 Jkt 244001 pages in length. Individuals submitting written comments should email their comments to the National Vaccine Program Office (nvpo@hhs.gov) at least five business days prior to the meeting. Dated: January 17, 2018. Roula Sweis, Deputy Director, National Vaccine Program Office. [FR Doc. 2018–01142 Filed 1–22–18; 8:45 am] BILLING CODE 4150–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Secretary; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of meetings of the Task Force on Research Specific to Pregnant Women and Lactating Women. The meetings will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Task Force on Research Specific to Pregnant Women and Lactating Women. Date: February 26–27, 2018. Time: February 26, 2018, 8:30 a.m. to 5:00 p.m.; February 27, 2018, 8:00 a.m. to 3:00 p.m. Agenda: The Task Force is charged with providing advice and guidance to the Secretary of HHS, regarding Federal activities related to identifying and addressing gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women, including the development of such therapies and the collaboration on and coordination of such activities. February 26th, 2018—Day 1 8:30 a.m.—Welcome and Opening Remarks 8:40 a.m.—Introductions 8:45 a.m.—Summary and Discussion of work products from meetings 1 and 2 10:45 a.m.—Follow-up on Task Force Request regarding Lessons learned from Pediatrics 1:15 p.m.—Effective communication strategies with health care providers and the public on information relevant to pregnant women and lactating women PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 3173 1:50 p.m.—Panel: Effective communication strategies with health care providers on information relevant to pregnant women and lactating women 3:30 p.m.—Panel: Effective communication strategies with the public on information relevant to pregnant women and lactating women. 4:10 p.m.—Discussion 5:00 p.m.—End of Day 1 February 27th, 2018—Day 2 8:00 a.m.—Recap from Day 1, Outline & Goals of Day 2 8:15 a.m.—Panel and open discussion to cover specific questions on the options for a plan or plans to identify and address gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women, including the development of such therapies. 12:45 p.m.—Discussion of Key Points related to topic: Effective communication strategies with health care providers and the public on information relevant to pregnant women and lactating women 1:30 p.m.—Discussion of Key Points related to topic: A plan to identify and address gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women, including the development of such therapies 2:15 p.m.—Review of Recommendations from TF1–3 2:45 p.m.—Action Items, Charge to Group 3:00 p.m.—Adjournment Place: 6710B Rockledge Drive, Room 1425/1427 (1st Floor), Bethesda, MD 20817. Contact Person: Ms. Lisa Kaeser, Executive Secretary, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 31 Center Drive, Room 2A03, MSC 2425, Bethesda, MD 20892, (301) 496–0536, kaeserl@mail.nih.gov. Public comments are welcome either by filing written comments and/or providing oral comments at the meeting. Oral comments from the public will be scheduled on February 26, 2018, from approximately 10:00 a.m.–10:45 a.m. Any member of the public interested in presenting oral comments on February 26, 2018, should submit a letter of intent, a brief description of the organization represented, and the oral presentation to Ms. Lisa Kaeser (Kaeserl@mail.nih.gov) by 5:00 p.m. on Monday, February 19, 2018. Written E:\FR\FM\23JAN1.SGM 23JAN1

Agencies

[Federal Register Volume 83, Number 15 (Tuesday, January 23, 2018)]
[Notices]
[Pages 3172-3173]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-01142]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: National Vaccine Program Office, Office of the Assistant 
Secretary for Health, Office of the Secretary, Department of Health and 
Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services is hereby giving notice that a 
meeting is scheduled to be held for the National Vaccine Advisory 
Committee (NVAC). The meeting will be open to the public; public 
comment sessions will be held during the meeting.

DATES: The meeting will be held on February 7 and 8, 2018. The meeting 
times and agenda will be posted on the NVAC website at https://www.hhs.gov/nvpo/nvac/meetings/ as soon as they become 
available.

ADDRESSES: U.S. Department of Health and Human Services, Hubert H. 
Humphrey Building, Great Hall, 200 Independence Avenue SW, Washington, 
DC 20201. The meeting can also be accessed through a live webcast on 
both days of the meeting. For more information, visit https://www.hhs.gov/nvpo/nvac/meetings/.
    Pre-registration is required for members of the public who wish to 
attend the meeting and who wish to participate in the public comment 
session. Individuals who wish to attend the meeting and/or participate 
in the public comment session should register at https://www.hhs.gov/nvpo/nvac/meetings/. Participants may also register by 
emailing [email protected] or by calling (202) 690-5566 and providing their 
name, organization and email address.

FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S. 
Department of Health and Human Services, Room 715H, Hubert H. Humphrey 
Building, 200 Independence Avenue SW, Washington, DC 20201. Phone: 
(202) 690-5566; email: [email protected].

[[Page 3173]]


SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and 
Human Services was mandated to establish the National Vaccine Program 
to achieve optimal prevention of human infectious diseases through 
immunization and to achieve optimal prevention against adverse 
reactions to vaccines. The NVAC was established to provide advice and 
make recommendations to the Director of the National Vaccine Program on 
matters related to the Program's responsibilities. The Assistant 
Secretary for Health serves as Director of the National Vaccine 
Program. During the February 2018 NVAC meeting, sessions will consist 
of presentations on vaccine innovation, including the current status of 
adjuvants in vaccines, universal influenza, and an overview on the 
Secretary of the Department of Health and Human Services' Report to 
Congress on Vaccine Innovation in response to the 21st Century Cures 
Act; a report out on the recently approved Presidential Advisory 
Council on Combatting Antibiotic-Resistant Bacteria Report, 
``Incentivizing the Development of Vaccines, Therapeutics, and 
Diagnostics to Combat Antibiotic Resistant Bacteria''; disparities in 
adult immunizations; and an update on strategies to support improving 
coverage for human papillomavirus vaccine. Please note that agenda 
items will be related to the charge of the Committee and are subject to 
change as priorities dictate. Information on the final meeting agenda 
will be posted prior to the meeting on the NVAC website: https://www.hhs.gov/nvpo/nvac/.
    Public attendance at the meeting is limited to the available space. 
Individuals who plan to attend in person and need special assistance, 
such as sign language interpretation or other reasonable 
accommodations, should notify the National Vaccine Program Office at 
the address/phone number listed above at least one week prior to the 
meeting. For those unable to attend in person, a live webcast will be 
available. More information on registration and accessing the webcast 
can be found at https://www.hhs.gov/nvpo/nvac/meetings/.
    Members of the public will have the opportunity to provide comments 
at the NVAC meeting during the public comment periods designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are also welcome to submit their written 
comments. Written comments should not exceed three pages in length. 
Individuals submitting written comments should email their comments to 
the National Vaccine Program Office ([email protected]) at least five 
business days prior to the meeting.

    Dated: January 17, 2018.
Roula Sweis,
Deputy Director, National Vaccine Program Office.
[FR Doc. 2018-01142 Filed 1-22-18; 8:45 am]
 BILLING CODE 4150-44-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.